Saniona’s recently published 2025 year-end report marks the conclusion of a year where the company transitioned from a partnership-heavy validation phase to a focused clinical execution strategy. Supported by significant upfront payments from major licensing deals, the company now prepares to advance three proprietary programmes toward the clinic in 2026. BioStock contacted Saniona’s CEO Thomas Feldthus for a comment.
Read the full interview at biostock.se:
Saniona enters clinical execution phase following transformational year
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/